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Using a quantitative quadruple 
immunoluorescent assay to 
diagnose isolated mitochondrial 
Complex I deiciency
Syeda T. Ahmed1, Charlotte L. Alston1,2, sila Hopton1,2, Langping He1,2, Iain P. Hargreaves3,4, 
Gavin Falkous1,2, Monika oláhová1, Robert McFarland1, Doug M. Turnbull1, Mariana C. 
Rocha1,5 & Robert W. Taylor1,2
Isolated Complex I (CI) deiciency is the most commonly observed mitochondrial respiratory chain 
biochemical defect, afecting the largest OXPHOS component. CI is genetically heterogeneous; 
pathogenic variants afect one of 38 nuclear-encoded subunits, 7 mitochondrial DNA (mtDNA)-encoded 
subunits or 14 known CI assembly factors. The laboratory diagnosis relies on the spectrophotometric 
assay of enzyme activity in mitochondrially-enriched tissue homogenates, requiring at least 50 mg 
skeletal muscle, as there is no reliable histochemical method for assessing CI activity directly in tissue 
cryosections. We have assessed a validated quadruple immunoluorescent OXPHOS (IHC) assay to 
detect CI deiciency in the diagnostic setting, using 10 µm transverse muscle sections from 25 patients 
with genetically-proven pathogenic CI variants. We observed loss of NDUFB8 immunoreactivity in all 
patients with mutations afecting nuclear-encoding structural subunits and assembly factors, whilst 
only 3 of the 10 patients with mutations afecting mtDNA-encoded structural subunits showed loss of 
NDUFB8, conirmed by BN-PAGE analysis of CI assembly and IHC using an alternative, commercially-
available CI (NDUFS3) antibody. The IHC assay has clear diagnostic potential to identify patients with 
a CI defect of Mendelian origins, whilst highlighting the necessity of complete mitochondrial genome 
sequencing in the diagnostic work-up of patients with suspected mitochondrial disease.
Mitochondrial diseases are a group of clinically heterogeneous disorders caused by dysfunction of the oxidative 
phosphorylation (OXPHOS) system. Accounting for approximately 30% of all cases, isolated Complex I (CI) dei-
ciency is the most frequently observed biochemical manifestation of an OXPHOS defect in patients, particularly 
within a paediatric setting1. With a relative molecular mass of 1MDa, mitochondrial CI (NADH: ubiquinone 
oxidoreductase) is the largest complex of the respiratory chain, oxidising NADH to NAD+ and playing a central 
role in both electron transfer and cellular energy (ATP) production. he complex is L-shaped in structure, con-
sisting of 2 fragments; a hydrophilic peripheral arm, which extends into the matrix of the mitochondria and a 
hydrophobic arm which is embedded into the inner mitochondrial membrane. he complex is comprised of 45 
subunits, 7 of which are encoded by the mitochondrial DNA (mtDNA) and the remaining 38 subunits encoded by 
the nuclear DNA (nDNA)2. his structure can be further divided into 3 functional modules: within the peripheral 
arm the N module (which binds and oxidizes NADH, providing electrons to the Fe-S clusters) and the Q module 
(where ubiquinone is reduced to ubiquinol) whilst the membrane arm contains the third module known as the P 
module which catalyses proton transfer3–8.
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he assembly of CI is a multistep process; recent studies propose a modular assembly model, in which ive 
assembly intermediates - termed Q/Pp-a, Pp-b, PD-a, PD-b and N - form separately before assembling into 
higher molecular mass intermediates to subsequently form the completed holoenzyme5. Despite diferences in 
the nomenclature of assembly intermediates, all proposed models described in the recent literature follow the 
same sequence of steps9–12. Briely, the irst step involves formation of the Q module, followed by the addition of 
the mitochondrial encoded ND1 core subunit (early stage of assembly). Next, the membrane arm is assembled, 
starting with the insertion of ND2, ND3, ND6, ND4L (PP-b module), ND4 (PD-a) and ND5 (PD-b) (early-mid 
stage assembly and mid-late stage assembly). he membrane arm comes together with the Q module (Q-P mod-
ule) prior to the addition of the pre-assembled N module and remaining subunits (last stage of assembly)5,9,13.
To date, pathogenic variants have been reported in all 7 mtDNA core structural subunits (ND1–6 and ND4L), 
21 of the nuclear-encoded subunits and 10 of the known CI assembly factors (reviewed in refs14,15). Further to 
this genetic heterogeneity, CI deiciency also exhibits considerable clinical heterogeneity with the spectrum rang-
ing from severe presentations including Leigh Syndrome (LS) and fatal infantile mitochondrial disease in early 
childhood through to Leber Hereditary Optic Neuropathy (LHON) and exercise-induced muscle weakness which 
develop during young adult life.
he diagnosis of mitochondrial disease oten uses a multidisciplinary approach including the histopatholog-
ical and biochemical assessment of tissue biopsy samples, usually skeletal muscle, as well as molecular genetic 
testing. Current histochemical methods to investigate mitochondrial disease are available for some OXPHOS 
components (e.g. the sequential assessment of cytochrome c oxidase (Complex IV, COX) and succinate dehy-
drogenase (Complex II, SDH)) but not all; no reliable histochemical assay is available to assess CI activity. Whilst 
validated biochemical assays can determine the activity of individual respiratory chain enzyme complexes, for 
example, CI by the spectrometric assay of rotenone-sensitive NADH oxidation, consensus diagnostic protocols 
are not widely adopted. Furthermore, most diagnostic laboratories request at least 50 mg of muscle tissue to reli-
ably measure enzyme activities, which represents a considerable proportion of the total amount of patient mate-
rial available, particularly in children. Additionally, the biochemical assay is known to only measure the redox 
activity of the peripheral arm of CI (containing the N-module and Q- module). herefore, patients with muta-
tions residing in the membrane arm (P-module) - where only the proton pumping ability is afected rather than 
electron transport - may show a ‘normal’ enzyme proile following biochemical assessment despite an underlying 
CI defect, although this may relect the level of mtDNA heteroplasmy in muscle tissue8. A conirmed diagnosis 
of isolated CI deiciency can facilitate appropriate molecular genetic testing to elucidate the underlying genetic 
cause, with screening of the mitochondrial genome preceding high throughput analysis of Mendelian candidates 
either by targeted gene panels, whole exome sequencing (WES) or whole genome sequencing (WGS)16.
Given the vast clinical and genetic heterogeneity associated with CI deiciency, accurate diagnosis is essen-
tial. A recently developed quadruple immunoluorescent assay to assess mitochondrial respiratory chain defects 
through the immunodetection of NDUFB8 (a CI subunit), COX-1 (a Complex IV subunit), porin (a mitochon-
drial mass marker) and laminin (a myoibre membrane marker) has been shown to provide an objective and reli-
able quantitative method for the assessment of CI and CIV protein abundance relative to the mitochondrial mass 
in individual muscle ibres within a single transversely-orientated, 10 µm muscle section17. We have extended this 
original study to assess CI status in skeletal muscle biopsies from 25 patients with proven pathogenic variants in 
proteins leading to a biochemical defect of isolated CI activity, including nuclear-encoded CI structural subunits, 
CI assembly factors, or one of the 7 mtDNA-encoded CI structural subunits. We demonstrate that the IHC assay 
has clear diagnostic potential, particularly for patients with Mendelian-inherited defects and propose that the 
IHC assay should form part of the multidisciplinary approach for the diagnostic investigation of patients with 
suspected CI deiciency.
Results
Mitochondrial Respiratory Chain (MRC) proiles. We assessed 25 skeletal muscle biopsies taken from 
patients with genetically-conirmed pathogenic variants either shown or predicted to cause isolated CI deiciency 
to validate a recently-developed immunoluorescence assay (IHC) within a diagnostic setting. he clinical, bio-
chemical and molecular genetic characteristics of this patient cohort are shown in Table 1. he IHC assay, detect-
ing CI subunit NDUFB8, CIV subunit COX-1 and porin (a marker of mitochondrial mass), was performed in 
all muscle sections (Supplementary Figs S1, S2 and S3), and ibres were classiied according to Z scores – where 
any ibres with a Z score under -3SD were classiied as deicient. he IHC results (NDUFB8 immunoreactivity), 
presented as a percentage of ibres deicient in CI – calculated by totalling the percentage of ibres classiied as 
negative, intermediate negative and intermediate positive ibres (Table 2) - were subsequently correlated with the 
diagnostic biochemical indings, presented as residual CI activity (Table 1).
Group 1: Nuclear-encoded CI structural subunits. All eight patients who have pathogenic variants in 
nuclear-encoded CI structural core or accessory subunits (Group 1) showed varying levels of decreased NDUFB8 
immunoreactivity (representing a decrease in NDUFB8 protein abundance) when compared to control mus-
cle (Supplementary Fig. S1). Further analysis revealed that the proportion of CI-immunodeicient ibres ranged 
between 39% and 99% across this group of patients. he mitochondrial respiratory chain proiles (Fig. 1), showing 
the NDUFB8 and COX-1 protein abundance in conjunction with mitochondrial mass in individual ibres, also 
illustrates this as most ibres analysed were outside of the normal range for NDUFB8 (Z-score from -3SD to 3 SD) 
– causing a shit in their distribution on the plot to the let - despite the normal levels of COX-1 (subunit of com-
plex IV) in virtually all ibres assessed (n = 131–13422 ibres analysed; dependent on the size of muscle section). 
hese indings were in agreement with the respiratory chain biochemical indings, where a decrease in residual 
CI activity was observed (Table 1).
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Patient Gender Adult/Paediatric Clinical Presentation Gene Genetic Defect
Residual Complex 
I activity
Mutation 
Load
Nuclear-encoded Complex I structural subunits
P1a F Paediatric
IUGR and oligohydramnios, 
FTT, mild hypertrophic 
cardiomyopathy
NDUFB3
Homozygous c.64 T > C, 
p.(Trp22Arg)
33% n.a.
P2b F Paediatric
IUGR. Acute life-threatening 
event, age 20 days, required 
intubation. Hypertrophic 
cardiomyopathy
NDUFB3
Homozygous c.64 T > C, 
p.(Trp22Arg)
32% n.a.
P3c F Paediatric
Oligohydramnios. IUGR. 
Poor feeding at birth. MRI 
brain and echocardiogram 
normal. Age-appropriate 
skills. Family history of 
previous neonatal death
NDUFB3
Homozygous c.64 T > C, 
p.(Trp22Arg)
35% n.a.
P4 F Paediatric Leigh syndrome NDUFS4
Compound heterozygous c.99-
1 G > A + c.416_417delinsC, 
p.(Glu139Alafs*50)
39% n.a.
P5 F Paediatric
Consanguineous, irst cousin 
parents; Leigh-like syndrome; 
elevated lactates
NDUFS4 Homozygous exon 3 and 4 deletion 37% n.a.
P6 M Paediatric
Infantile-onset mitochondrial 
disease; marked lactic acidosis
NDUFS6
Homozygous c.316_319delGAAA, 
p.(Glu106Glnfs*41)
5% n.a.
P7 F Paediatric Leigh syndrome NDUFS2
Homozygous c.998 G > A, 
p.(Arg333Gln)
42% n.a.
P8 F Paediatric
Leigh-like syndrome; elevated 
serum lactates
NDUFS3
Homozygous c.642_644delTGA, 
p.(Asp214del)
26% n.a.
Nuclear-encoded Complex I assembly factors
P9 F Paediatric
Leigh-like syndrome; elevated 
lactates
NDUFAF6
Compound heterozygous 
c.805 C > T, p.(His269Tyr) 
and c.581-7 A > G, p.(Leu193_
Gly194insValIle)
26% n.a.
P10 F Paediatric
Lethal infantile mitochondrial 
disease presentation; 
presented day 1 with 
persistent lactic acidosis; died 
at 9 weeks
NDUFAF6
Homozygous c.659 C > A, 
p.(hr220Lys)
45% n.a.
P11 F Paediatric
Presented at 8 months; 
developmental regression, 
rotatory nystagmus 
bilaterally; elevated blood 
and CSF lactate; extensive 
basal ganglia and brainstem 
changes on MRI
NDUFAF5
Compound heterozygous 
c.826 C > T, p.(Arg276*) and 
c.848 C > T, p.(Ala283Val)
44% n.a.
P12 M Paediatric
Myoclonic seizures, 
developmental delay
FOXRED1
Compound heterozygous 
c.612_615dup, p.(Ala206Serfs*15) 
and c.1261 G > A, p.(Val421Met)
31% n.a.
P13 M Paediatric
Hypertrophic 
cardiomyopathy at birth; 
severe metabolic acidosis 
(18–30 mmol/L); died at 2 
days of age
ACAD9
Compound heterozygous 
c.868 G > A, p.(Gly290Arg) and 
c.976 G > C, p.(Ala326Pro)
13% n.a.
P14 M Adult
Exercise intolerance, muscle 
cramps, elevated serum 
lactate
ACAD9
Compound heterozygous 
c.1150 G > A, p.(Val384Met) and 
c.1168 G > A, p.(Ala390hr)
13% n.a.
P15d M Adult
Exercise intolerance, unable 
to perform sustained 
aerobic exercise; normal 
strength; normal ECG and 
echocardiogram; normal 
resting lactate, normal CK
TMEM126B
Homozygous c.635 G > T, 
p.(Gly212Val)
36% n.a.
Mitochondrial DNA-encoded Complex I structural subunits
P16e F Adult
Exercise intolerance, 
persistent lactic acidaemia
MTND1 m.3356 T > C, p.(Met17hr) 3% 92%
P17 M Paediatric Leigh syndrome MTND3 m.10158 T > C, p.(Ser34Pro) 44% 90%
P18 M Paediatric Leigh syndrome MTND3 m.10197 G > A, p.(Ala47hr) n.d. 93%
P19 M Paediatric Leigh syndrome MTND5 m.13514 A > G, p.(Asp393Gly) 27% 66%
P20f F Paediatric
Chronic renal failure, 
myopathy and persistent 
lactic acidosis
MTND5 m.12425delA, p.(Asn30hrfs*7) 16% 85%
P21 F Paediatric
Bilateral ptosis, 
ophthalmoplegia, pyramidal 
tract signs, elevated blood and 
CSF lactates
MTND5 m.13094 T > C, p.(Val253Ala) 59% 58%
Continued
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Group 2: Nuclear-encoded CI assembly factors. Similar to patients in Group 1, all seven patients with 
pathogenic variants in nuclear-encoded assembly factors (Group 2), displayed a severe loss of NDUFB8 subu-
nit immunoreactivity (Supplementary Fig. S2). With the exception of P11, further quantiication showed that 
the percentage of CI-deicient ibres was > 96%, highlighting the severe loss of NDUFB8. Speciically, the assay 
detected a complete loss of NDUFB8 immunoreactivity (100% CI-deicient ibres) in patients P13, P14 and P15 
all of whom had pathogenic variants in either the ACAD9 or TMEM126B genes; these encode CI assembly factors 
involved in the biogenesis of the proximal part of the P module (PP). Only P11, who has compound heterozygous 
pathogenic variants in the NDUFAF5 gene, encoding a CI assembly factor involved in an early step of the biogen-
esis of the holoenzyme, maintained a relatively normal level of NDUFB8 (26% CI-deicient ibres). As previously 
observed in patients from Group 1, the mitochondrial respiratory chain proiles from patients in Group 2 (Fig. 2) 
similarly showed a “shiting to the let”, but to a greater extent. Again, the IHC indings correlated with available 
biochemical results which show a more severe decrease in muscle CI activity (Table 1).
Patient Gender Adult/Paediatric Clinical Presentation Gene Genetic Defect
Residual Complex 
I activity
Mutation 
Load
P22 M Adult
Mitochondrial myopathy, 
elevated lactates
MTND5 m.13513 G > A, p.(Asp393Asn) 39% 60%
P23 M Paediatric Leigh syndrome MTND5 m.13513 G > A, p.(Asp393Asn) 38% 77%
P24 F Adult
Elevated CK, muscle pain and 
fatigue, myopathy
MTND5 m.13513 G > A, p.(Asp393Asn) 100% 45%
P25 M Paediatric
Failure to strive, myopathy, 
increased brainstem signal on 
MRI, lactic acidosis
MTND5 m.13513 G > A, p.(Asp393Asn) 100% 63%
Table 1. Clinical, biochemical and molecular genetic characteristics of our patient cohort with isolated 
Complex I deiciency. Residual Complex I activities, normalised to the activity of the matrix marker enzyme 
citrate synthase, are expresses as a percentage of mean control values. Residual Complex I activity and 
mtDNA mutation load measured in muscle. Key: IUGR, intrauterine growth restriction; FTT, failure to 
thrive; ECG, electrocardiogram; CK, creatinine kinase; a,b,c,d,epublished patients: aP1 = Patient 3 in Alston 
et al.16, bP2 = Patient 2 in Alston et al.16, cP3 = Patient 6 in Alston et al.16, dP15 = Patient S1 in Alston et al.20, 
eP16 = Patient 1 in Gorman et al.27, eP20 = Patient published in Alston et al.26, F; Female, M; Male, n.a.; not 
applicable, n.d.; not determined.
Patient ID
IHC indings - % of 
CI deicient ibres
Total number of 
ibres analysed
Nuclear-encoded Complex I 
structural subunits
P1 79% 4372
P2 93% 559
P3 39% 13422
P4 98% 5964
P5 89% 4683
P6 79% 880
P7 99% 5337
P8 96% 7154
Nuclear-encoded Complex I 
assembly factors
P9 99% 9504
P10 96% 5355
P11 26% 7352
P12 96% 1708
P13 100% 2684
P14 100% 239
P15 100% 131
Mitochondrial DNA-
encoded Complex I 
structural core subunits
P16 92% 696
P17 90% 5842
P18 0% 7302
P19 0% 2427
P20 100% 3795
P21 0% 1311
P22 0% 3341
P23 0% 2730
P24 0% 675
P25 0% 785
Table 2. Percentage of Complex I (CI) deicient ibres detected with the IHC assay.
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Figure 1. Mitochondrial respiratory chain expression proile linking complex I, complex IV and porin levels in 
patients with isolated Complex I deiciency caused by defects in nuclear-encoded Complex I subunits. Graphs 
show complex I and complex IV expression proile from (A) Normal adult control and patients with (B–D) 
homozygous c.64T>C, p.(Trp22Arg) NDUFB3 variant, P1–n = 4372 ibres analysed, P2–n = 559, P3–n = 13422 
(E) compound heterozygous NDUFS4 variant, P4, n = 5964 (F) Homozygous exon 3 and 4 deletion in NDUFS4, 
P5, n = 4683 (G) homozygous NDUFS6 variant, P6, n = 880 (H) Homozygous NDUFS2 variant, P7, n = 5337 
(I) Homozygous NDUFS3 variant, P8, n = 7154. Each dot represents a single muscle ibre, colour co-ordinated 
according to its mitochondrial mass: very low – blue, low – light blue, normal – beige, high – orange, very high 
- red. Black dashed lines represent the SD limits for the classiication of the ibres. Lines adjacent to X and Y 
axis represent the levels of NDUFB8 and COX-1: beige: normal (<−3), light beige: intermediate (+) (−3 to 
−4.5), light blue: intermediate (−) (−4.5 to −6) and blue: deicient (>−6). Bold dashed lines indicate the mean 
expression level of normal ibres.
www.nature.com/scientificreports/
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IHC shows variable results in patients with mutations in mtDNA-encoded CI subunits (Group 3). 
Patients harbouring mutations in mtDNA genes encoding core structural subunits of Complex I (Group 3, 
n = 10) showed more heterogeneous results. he IHC assay detected 100% CI-deicient ibres, representing a 
complete loss of NDUFB8 immunoreactivity, in three previously-reported patients with high levels of pathogenic 
mtDNA variants in muscle; P16 who has a m.3356 T > C, p.(Met17hr) MTND1 variant, P17 who harbours a 
m.10158 T > C, p.(Ser34Pro) MTND3 variant and P20 who harbours a m.12425delA MTND5 frameshit muta-
tion (see Supplementary Fig. S3 and Table 2). As expected, the mitochondrial respiratory chain proiles for these 
three patients were all shited to the let, consistent with the loss of NDUFB8 immunoreactivity associated with 
preserved COX-I immunoreactivity (Fig. 3).
he remaining 7 patients (P18, P19, P21, P22, P23, P24 and P25) showed NDUFB8 immunoreactivity similar 
to control muscle (Supplementary Fig. S4 and Table 2). he mitochondrial respiratory chain proiles demonstrated 
normal respiratory chain function as all ibres fell within the normal range (with Z scores between -3SD and 3 SD) 
(Fig. 3). Of these 7 patients, P22- P25 all harbour a common pathogenic m.13513 G > A, p.(Asp393Asn) MTND5 
variant, P19 harbours a m.13514 A > G, p.(Asp393Gly) variant, P21 harbours a m.13094 T > C, p.(Val253Ala) 
variant whilst P18 has high levels of a m.10197 G > A, p.(Ala393hr) MTND3 variant. Detection of normal levels 
of immunoreactive NDUFB8 subunit in these patients could be due to these variants only afecting the catalytic 
function of CI rather than the assembly of the enzyme complex.
Patients with mutations in mtDNA-encoded CI subunits and normal NDUFB8 proile also dis-
play normal NDUFS3 levels. Since interrogation of NDUFB8 immunoreactivity failed to detect CI dei-
ciency in 7 of the 10 patients with mtDNA-encoded structural CI mutations, we further investigated whether any 
deiciency could be detected using an alternative, but commercially-available CI antibody targeting NDUFS3 – a 
subunit which is integrated during the early stage of complex I assembly. he IHC assay was performed on 10µm 
muscle sections from P18, P19, P20, P21, P23, P4 and P25 using antibodies against NDUFS3, porin, COX-I and 
laminin, and showed normal NDUFS3 immunoreactivity (Supplementary Fig. S5). As shown in Fig. 4, the mito-
chondrial respiratory chain proile for P20 shows a shit of ibres to the let whilst for all the remaining patients 
also tested with NDUFS3 fall into the normal range – these indings are the same as the assessment with the 
NDUFB8 antibody
BN-PAGE assessing the steady-state levels of fully-assembled Complex I. To further interrogate 
the IHC results observed in the subset of patients displaying normal NDUFB8 and NDUFS3 immunoreactivity, 
we performed BN-PAGE analysis to assess the steady-state levels of fully assembled CI (980 kDa) where muscle 
was available (P18, P19, P21, P22, P23 and P25). P17 was also included as a positive control in this analysis given 
the IHC assay had shown down-regulated levels of NDUFB8 immunoreactivity. Samples prepared for BN-PAGE 
analysis retain OXPHOS complexes in their structural and active form, permitting the investigation of any efects 
on the assembly of the holoenzyme or catalytic activity. Since we had previously measured residual CI activity 
spectrophotometrically, we only assessed the levels of fully assembled complex I, using complex II assembly as a 
control.
Analysis of muscle mitochondrial fractions by BN-PAGE revealed a decrease in steady-state levels of 
fully-assembled CI in P17, P18, P23 and, P24 (Fig. 5) when compared to controls, indicating that the mutations 
harboured by these patients afect levels of fully-assembled CI. As complex II activity is normal in these patients, 
we targeted SDHA subunit and used the steady-state levels of assembled complex II (detected by immunoreactiv-
ity against the SDHA subunit) as a loading control. By contrast, patients P19, P21 and P22 showed normal levels 
of fully assembled CI, in line with the IHC assay results, therefore likely indicating that these mutations afect the 
activity of the complex rather than CI assembly.
he level of CI was also normal in P25, correlating with the indings from the IHC (Fig. 5). Furthermore, the 
residual biochemical CI activity was also 100%, indicative that the m.13513 G > A, p.(Asp393Asn) variant in this 
case has no major efect on the activity or assembly of CI despite the relatively high level of mtDNA heteroplasmy 
(Table 1).
Discussion
his study aimed to assess and validate the application of a recently developed quadruple immunoluorescent 
OXPHOS assay to the diagnosis of patients with isolated mitochondrial CI deiciency. he IHC assay, which 
detects NDUFB8 as a marker of CI integrity, was successful in detecting CI deiciency in 18 of the 25 patients 
tested, including all patients with pathogenic variants in nuclear genes encoding CI structural subunits and 
assembly factors. However, only 3 of the 10 patients harbouring pathogenic mtDNA variants showed a con-
sistent decrease in NDUFB8 immunoreactivity and thus protein abundance, later conirmed using a further 
commercially-available antibody against NDUFS3, another key component of CI. We chose to optimise the IHC 
assay using a commercially-available and widely-used antibody against NDUFB8. he subunit is assembled at the 
mid/late stage of assembly, alongside the mtDNA-encoded core structural subunit, ND5. Although, it would have 
been preferable to use an antibody targeting a mtDNA-encoded subunit, such as ND1 (interrogating the early 
stage of CI assembly), there are currently no robust, commercially-available antibodies raised against this or other 
mtDNA subunits, important to consider if the assay is to be adopted across diagnostic centres.
Using this assay, we could detect CI deiciency in patients that harboured mutations in nuclear genes encoding 
either the accessory, (P1, P2, P3 = NDUFB3 subunit of the P-D region of the P-module, P4 and P5 = NDUFS4 
subunit of the N-module, P6 = NDUFS6 subunit of the N-Module, P7 = NDUFS2 subunit of the Q-module) or 
core subunits (P8 = NDUFS3 subunit of the Q-module) of CI, in line with the biochemical indings. Of inter-
est, we note that despite patients 1, 2 and 3 harbouring the same genetic variant (p.Trp22Arg in NDUFB3) and 
similar residual CI activities, the IHC indings showed variable levels of NDUBF8 immunoreactivity (P1 = 79%, 
www.nature.com/scientificreports/
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Figure 2. Mitochondrial respiratory chain expression proile linking complex I, complex IV and porin levels in 
patients with isolated Complex I deiciency caused by defects in nuclear-encoded Complex I assembly factors. 
Graphs show complex I and complex IV expression proile from patients with (A) Compound heterozygous 
NDUFAF6 variant, P9, n = 9504 ibres analysed (B) Homozygous NDUFAF6 variant, P10, n = 5355 (C) 
Compound heterozygous NDUFAF5 variant, P11, n = 7352 (D) Compound heterozygous FOXRED1 variant, 
P12, n = 1708 (E–F) Compound heterozygous ACAD9 variant, (E = P13, n = 2684, F = P14, n = 239) (G) 
Homozygous TMEM126B variant, P15, n = 131. Each dot represents a single muscle ibre, colour co-ordinated 
according to its mitochondrial mass: very low – blue, low - light blue, normal – beige, high – orange, very high -  
red. Black dashed lines represent the SD limits for the classiication of the ibres. Lines adjacent to X and Y axis 
represent the levels of NDUFB8 and COX-1: beige: normal (<−3), light beige: intermediate (+) (−3 to −4.5),  
light blue: intermediate (−) (−4.5 to −6) and blue: deicient (>−6). Bold dashed lines indicate the mean 
expression level of normal ibres.
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Figure 3. Mitochondrial respiratory chain expression proile linking complex I (NDUFB8), complex 
IV and porin levels in patients with isolated Complex I deiciency caused by defects in mtDNA-encoded 
Complex I subunits. Graphs show complex I and complex IV expression proile from patients with (A) 
m.3356T>C MTND1 variant, P16, n = 696 ibres analysed (B) m.10158T>C MTND3 variant, P17, n = 5842 
(C) m.10197G>A MTND3 variant, P18, n = 7302 (D) m.13514A>G MTND5 variant, P19, n = 2427 
(E) m.12425delA MTND5 variant, P20, n = 3795 (F) m.13094T>C MTND5 variant, P21, n = 1311 (G) 
m.13513G>A MTND5 variant, P22, n = 3341 (H) m.13513G>A MTND5 variant, P23, n = 2730 (I) 
m.13513G>A MTND5 variant, P24, n = 675 (J) m.13513G>A MTND5 variant, P25, n = 785. Each dot 
represents a single muscle ibre, colour co-ordinated according to its mitochondrial mass: very low – blue, low 
- light blue, normal – beige, high – orange, very high - red. Black dashed lines represent the SD limits for the 
classiication of the ibres. Lines adjacent to X and Y axis represent the levels of NDUFB8 and COX-1: beige: 
normal (<−3), light beige: intermediate (+) (−3 to −4.5), light blue: intermediate (−) (−4.5 to −6) and blue: 
deicient (>−6). Bold dashed lines indicate the mean expression level of normal ibres.
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Figure 4. Mitochondrial respiratory chain expression proile linking complex I (NDUFS3), complex 
IV and porin levels in patients with Isolated complex I deiciency caused by defects in mtDNA-encoded 
Complex I subunits. Graphs show complex I and complex IV expression proile from patients with (A) 
m.12425delA MTND5 variant, P20, n = 5536 ibres analysed (B) m.10197G>A MTND3 variant, P18, 
n = 6645 (C) m.13514A>G MTND5 variant, P19, n = 2730 (D) m.13094T>C MTND5 variant, P21, n = 3979 
(E) m.13513G>A MTND5 variant, P23, n = 10009 (F) m.13513G>A MTND5 variant, P24, n = 575 (G) 
m.13513G>A MTND5 variant, P25, n = 1168. Each dot represents a single muscle ibre, colour co-ordinated 
according to its mitochondrial mass: very low – blue, low - light blue, normal – beige, high – orange, very high 
- red. Black dashed lines represent the SD limits for the classiication of the ibres. Lines adjacent to X and Y 
axis represent the levels of NDUFB8 and COX-1: beige: normal (<−3), light beige: intermediate (+) (−3 to 
−4.5), light blue: intermediate (−) (−4.5 to −6) and blue: deicient (>−6). Bold dashed lines indicate the mean 
expression level of normal ibres.
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P2 = 93% P3 = 39%). However, these indings are consistent with the steady-state levels of the NDUFB8 subunit 
of CI on western and BN-PAGE originally reported by Alston and colleagues, where it was shown that P1 and P2 
(P3 and P2 respectively in ref.16) had decreased protein levels when compared to P3 (P6 in ref.16). Taken together, 
the collective data highlight the potential of the IHC assay to be a diagnostic tool for such cases and shows 
that all mutations in Group 1 exerted a similar efect on steady-state levels of fully assembled CI as previously 
documented16,18,19.
Similarly, the IHC assay was able to diagnose all patients with genetic variants in CI assembly factors. As 
expected, mutation of these genes led to a decrease in CI assembly and accordingly our IHC assay recorded a 
marked loss of CI immunoreactivity in many of the ibres analysed; a complete loss of NDUFB8 immunoreactiv-
ity (100% CI-deicient ibres) was noted in P13, P14 (ACAD9 variants) and P15 (TMEM126B variant), consistent 
with previous reports of severe CI deiciency in ACAD9 and TMEM126B mutations20–23. hese two assembly 
factors, alongside with NDUFAF1, ECSIT and TIMMDC1 form the ‘Mitochondrial CI assembly’ (MCIA) com-
plex24 which is associated with the assembly of the P-P submodule (that contains the ND2, ND3, ND4-L and ND6 
mitochondrial- encoded subunits). Since depletion of TMEM126B leads to the accumulation of the Q/PP-a (Q 
module-ND1) intermediate, it seems that NDUFB8 is unstable and as such degraded before the complete assem-
bly of the holoenzyme, explaining why a complete loss of NDUFB8 protein is observed in all ibres24,25.
For patients with pathogenic variants in mtDNA-encoded CI structural subunits, the IHC assay was able 
to detect CI deiciency in 3 patients (P16, P17 and P20). he m.12425delA MTND5 mutation in P20 leads to a 
truncated form of the ND5 subunit which has previously been shown to have a severe impact on CI assembly26. 
his was supported by our IHC results where we observed a complete loss of NDUFB8 immunoreactivity (100% 
CI-deicient ibres). Similarly, P16 harbours a m.3356 T > C, p.(Met17hr) MTND1 variant at high levels in mus-
cle associated with a severe defect in CI assembly27, corroborating our IHC results ( > 90% CI-deicient ibres). 
Finally, P17 harbours a m.10158 T > C, p.(Ser34Pro) MTND3 variant, leading to a marked decrease in NDUFB8 
immunoreactivity and steady-state levels of fully-assembled CI; together these results show that the IHC assay 
conidently detects the deiciency associated with mtDNA variants which severely impact upon CI assembly.
he remaining 7 patients, where normal NDUFB8 (and, where tested, NDUFS3) immunoreactivity was 
detected, harbour well-characterised pathogenic variants in either the MTND5 (P19, P21, P22, P23, P24 and 
P25) or MTND3 genes (P18). It has been shown that missense variants in these proteins predominantly afect 
CI redox activity whereas mutations in the MTND1, MTND2 and MTND6 genes have a more severe impact on 
complex assembly28–33. We speculate that the patient mutations in which we found normal levels of CI based on 
both IHC and BN-PAGE analysis (P19: MTND5, m.13514 A > G, p.(Asp393Gly); P21: MTND5, m.13094 T > C, 
p.(Val253hr); P22: MTND5, m.13513 G > A, p.(Asp393Asn)) are likely to only afect the catalytic site of the 
holoenzyme without disturbing CI stability and assembly. In line with this, the m.13514 A > G MTND5 mutation 
(P19) has been shown to afect the redox activity of CI34–36. he change of amino acid at position 393 (which is 
part of a putative quinone-reactive site of the enzyme), causes a loss of the putative quinone-reactive site, thereby 
Figure 5. Analysis of Complex I assembly by BN-PAGE. Complex I assembly proiles were analysed using one 
dimensional blue native polyacrylamide gel electrophoresis (BN-PAGE) (4-16% gradient). Analysis showed a 
decrease in fully-assembled CI in patients P17, P18, P23 and P24, whilst normal assembly is seen in patients 
P19, P21, P22 and P25. Complex II was used a loading control. Both OXPHOS complexes were detected by 
immunoblotting using subunit speciic antibodies – NDUFB8 (Complex I) and SDHA (complex II). he 
original, full length blots are included in the Supplementary Information File (Supplementary Fig. S6).
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leading to a decline in CI activity37,38 and validating the IHC indings. Patients harbouring mtDNA variants which 
only afect CI catalytic activity are likely to show normal IHC proiles.
Furthermore, many studies have also shown that defects in the MTND3 and MTND5 genes display variable 
biochemical phenotypes; either decreased redox activities as determined by biochemical spectrophotometric 
assays, decreased levels of fully assembled CI or both18,31,34–36,39–45. his supports the variability found in our 
results as the m.13513 G > A, p.(Asp393Asn) variant, the most frequently occurring mutation in the MTND5 
gene43, can manifest difering efects: either a decrease in fully assembled CI (P23 and P24) or normal levels of 
assembled CI (P25)18,34,35,38–43. Somewhat surprisingly, P25 (mean m.13513 G > A heteroplasmy level of 63% in 
muscle) also presented with normal redox activity and CI assembly proiles, likely due to the confounding factor 
of mutant load. While most pathogenic mtDNA variants cause a biochemical defect only when the levels of muta-
tions mtDNA exceeds 80–90%46, lower thresholds are reported in patients with CI deiciency due to structural 
subunit mutation35,41. In the case of P25, it could be possible that the pathogenic threshold in this patient is higher, 
thereby explaining the absence of a biochemical defect despite the presence of relatively high mutation levels and 
an associated clinical phenotype.
Finally, we detected normal NDUFB8 immunoreactivity but decreased levels of fully-assembled CI in patient 
P18 harbouring a pathogenic m.10197 G > A, p.(Ala47hr) MTND3 variant. his has previously been associated 
with decreased redox activity and diminished levels of fully-assembled CI31,44,45; unfortunately, due to inadequate 
amounts of skeletal muscle tissue from this patient, we were unable to verify if an efect on activity was also 
present. Our IHC data indicate, however, that the subunit must be present as the NDUFB8 level was normal. 
Interrogating NDUFS3 levels also showed normal results, suggesting that our IHC assay is less able to identify CI 
defects associated with pathogenic variants causing milder defects in CI assembly.
We believe our assay contributes to available diagnostic tools for studying mitochondrial diseases which 
are typiied by extensive biochemical, genetic and clinical heterogeneity. Whilst all patients in our cohort with 
Mendelian CI defects showed a decrease or complete loss of NDUFB8 immunoreactivity and redox activity, 
patients with mtDNA variants afecting CI subunits displayed variable biochemical phenotypes. Consequently, we 
emphasise the importance of complete mitochondrial genome sequencing in the diagnostic work up of patients 
with suspected mitochondrial disease, to identify possible pathogenic variants associated with clinical symptoms 
that may result from mutation of mtDNA-encoded structural CI subunits.
In conclusion, our study has accessed and validated the use of a quadruple IHC assay in a diagnostic setting for 
identifying patients with suspected CI deiciency using a single 10 µm transverse skeletal muscle section. We have 
been able to directly detect varying levels of NDUFB8 protein abundance at a single cell level, a key advantage of 
the IHC assay in comparison to current histochemical and histological methodologies. Given these data, we have 
been able to provide evidence that this assay has clear diagnostic potential for patients with CI deiciency, particu-
larly for those with mutations afecting nuclear-encoded genes, which account for ~75–80% of genetic causes of 
CI deiciency. Whilst the assay is not suiciently sensitive to identify a biochemical defect associated with some 
very well-characterised mtDNA – or rare catalytic defects afecting either mtDNA-encoded or nuclear-encoded 
CI subunits – we believe that a combination of the quadruple IHC assay, in tandem with full mitochondrial 
genome sequencing and standard biochemical assays, can be used to investigate likely genetic causes of CI dei-
ciency in patients with mitochondrial disease, especially when muscle biopsy sample sizes are small necessitating 
the analysis of cryosectioned material.
Methods
Tissue Samples and patient cohort. 25 skeletal muscle biopsies (quadriceps muscle) of patients -both 
paediatrics (<16 years of age) and adults (>16 years of age), who have been investigated for mitochondrial 
disease and shown to have genetically-conirmed pathogenic variants attributed to isolated CI deiciency were 
included in this study (see Table 1 for detailed information). Measurements of the enzymatic activities of respira-
tory chain complexes were undertaken at one of two Mitochondrial Diagnostic laboratories, the NHS Highly 
Specialised Services located within the Wellcome Centre for Mitochondrial Research at Newcastle University or 
the Neurometabolic Laboratory at University College London Hospitals (UCLH). Muscle biopsy referral, enzyme 
measurements and genetic studies were all undertaken as part of the diagnostic work-up of these patients for 
suspected mitochondrial disease. All samples were obtained and used with informed consent. his study was 
approved and performed under the ethical guidelines issued by the Newcastle and North Tyneside Local Research 
Ethics Committees (reference 09/H0906/75) and complied with the Declaration of Helsinki. Control muscle was 
obtained from patients who were undergoing anterior cruciate ligament (ACL) operations and shown to have 
normal respiratory enzyme activities.
Quadruple Immunohistochemistry. Quadruple immunohistochemistry was undertaken on 10 µm sec-
tions as described by Rocha et al.17. Briely, sections were incubated with the primary antibodies (Supplementary 
Table S1) overnight at 4 °C followed by a three wash steps for 10 minutes. his was followed by incubation with 
secondary antibodies for 2 hours in 4 °C and a further incubation step with streptavidin conjugated with Alexa 
647 for 2 hours at 4 °C (Supplementary Table S1). Sections were then mounted using ProLong gold antifade rea-
gent. No-primary antibody control (NPC) sections (incubated only with the anti-laminin primary antibody), 
were processed alongside each muscle sample.
Image Acquisition. Tiled luorescent images were taken at x20 magniication using a Zen 2011 (blue edi-
tion) sotware and Zeiss Axio imager MI microscope, equipped with a motorised stage, an AxioCam digital cam-
era and ilter cubes detecting wavelengths at 488 nm, 546 nm, 647 nm and 750 nm. Exposure times were set for 
each channel to avoid over saturation – the same exposure times were then maintained across all cases.
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Statistical Analysis. Densitometry measurements. Fluorescent images were analysed using an in-house 
analysis sotware coded for by MatLab 2015a. he laminin immunoluorescence (750 channel) was used to detect 
ibres automatically. Any unwanted surfaces including those over background, ibres with poor morphology or 
folded were removed. he surfaces allowed for the measurement of mean intensity/optical density (OD) of 488 
(COX-1), 546 (Porin) and 647 (NDUFB8) in each individual ibre. he same procedure was repeated for each 
NPC in order to determine the levels of non-speciic binding
Data Analysis. Following image analysis, excel iles containing the mean ODs for each case were analysed using 
an in-house web-based tool as previously described14, along with the statistical calculations within the manuscript 
Rocha and colleagues17. his analysis determined the Z scores for porin, COX-1 and NDUFB8 based on their 
expected levels, which were derived using data obtained from control muscle sections. Fibres were classiied based on 
the SD limits into groups of NDUFB8 and COX-1 levels; >−3 = normal, −3 to −4.5 = intermediate positive, −4.5 to 
−6 = intermediate negative and <−6 = deicient/negative. Fibres were also classiied into levels of porin according 
to Z scores (Z-score: “very low” (porin_Z < −3 SD), “low” (porin_Z between −3 SD and −2 SD), “normal” (porin_Z 
between −2 SD and +2 SD), “high” (porin_Z between +2 SD and +3 SD) and “very high” (porin_Z above +3 SD)).
Blue Native–Polyacrylamide Gel Electrophoresis (BN-PAGE). Mitochondrial fractions from both 
controls and patient muscle were prepared for Blue Native–Polyacrylamide Gel Electrophoresis (BN-PAGE) as 
previously described in detail by Olahova et al., 2015. he protein concentration of samples was determined using 
the Pierce BCA protein assay kit and absorption spectrophotometry measured at 562 nm. A minimum of 150ug 
of muscle mitochondria extracts were loaded on a native 4–16% BisTris gel (Life technologies) and electropho-
retically separated in irst dimension according to the NOVEX NativePAGETM Bis-Tris Gel system instructions 
(2 hours, 250 volts). Proteins were transferred onto a polyvinylidene luoride (PVDF) membrane (Immobilon-P, 
Millipore Corporation) through wet transfer. hereater, the membrane was ixed in 8% acetic acid, washed and 
blocked with 5% milk for 1 hour at room temperature. Membrane was then subjected to standard immunoblot-
ting analysis of OXPHOS complexes using primary and horseradish peroxidise conjugated secondary antibodies 
against NDUFB8 (980 kDa CI holoenzyme) and SDHA (140 kDa) (Supplementary Table S2).
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